

## CURRICULUM VITAE

### Personal data

Name	Riitta Pirkko Tuulikki Lassila (former Palomäki)
Mailing address	Westendintie 4 C FIN-02160 Espoo, FINLAND
Telephone	+358-9-4127 599, home, mobile +358-40-5175547
Birth date	June 25, 1957
Birth place	Outokumpu, Finland
Academic degree	M.D., Ph.D Professor in Coagulation Medicine
Office address	Helsinki University Central Hospital, Coagulation disorders, Haematology and Laboratory Services, Comprehensive Cancer Center PB 372, FIN-00029 HUS Helsinki, Finland
Office telephone	(358-9)-471 75533
Mobile	(358-40)-5175547
fax	(358-9)-471 74504
e-mail	riitta.lassila@hus.fi home: riitta.lassila@kolumbus.fi

### Education

1968-76	High School and College studies at Tapiolan Yhteiskoulu, Espoo, Finland
1977-83	University of Helsinki, Faculty of Medicine, Licentiate of Medicine and Legitimated Physician
1989	Academic thesis (Ph.D) in University of Helsinki, Faculty of Medicine
1996	Docent in experimental medicine, University of Helsinki
2003	Specialization in Internal Medicine, University of Helsinki
2005	Legal rights for practice in Sweden
2013	Professor in Coagulation Medicine
Languages	Finnish, English, Swedish, (German)

### Professional experience

Feb-Sep 1983	General practitioner in the community of Vihti, Finland
Oct 1983-Apr 84	Resident, Department of Radiology at Helsinki University Central Hospital, (HUCH), Fourth Department of Surgery
May 1984-Dec 84	Resident, Department of Anaesthesiology, Fourth Department of Surgery, HUCH
Jan-Apr 1985	Research Residency, Fourth Department of Surgery, HUCH
May -Sep 1985	Resident, First Department of Internal Medicine, HUCH
Oct 1985-Mar 87	Research Fellow: Wihuri Research Institute
Apr 1987-Nov 89	Research Fellow: Mount Sinai Medical Center, Division of cardiology, New York, NY, USA
Jan 1990-Dec 2003	Assistant scientific director: Wihuri Research Institute
Jan 1999-July 2000	Resident, Internal Medicine, HUCH
Aug 2000-Dec 2001	Consultant in Thrombosis and Hemostasis, Internal Medicine, HUCH

Jan 2002-May 2006	Head, Coagulation disorders, Internal Medicine, Hematology, HUCH
May 2006-Sept 2006	Head, Coagulation disorders, Hematology, Karolinska Sjukhuset, Stockholm, Sweden
Oct 2006- Jan 2009 -	Head, Coagulation disorders, Hematology and Laboratory Services, HUCH Chief Scientific Officer, Aplagon OY

Fellowships and grants

Jul 1986	awarded by Wihuri Research Institute to attend the Second Advanced Course of Thrombosis and Haemostasis by European Thrombosis Research Organisation in Maastricht, Holland
Mar 1987	Research Fellowship, Meilahti-Foundation, Finland
Dec 1987	Research Fellowship for academical thesis, Aarne Koskelo Foundation
Feb 1988	Research Fellowship, Paulo Foundation
Oct 1988	Helsinki Heart Study Fellowship
Nov 1988	Jenni and Antti Piponius Foundation Fellowship
Sept 1989	Paavo Nurmi Foundation Fellowship
Dec 1989	Research Fellowship, Aarne Koskelo Foundation
Dec 1990	Research Fellowship Paavo Nurmi Foundation and the fellowship of the Finnish Heart Research Foundation
Sept 1992	Research Fellowship Paavo Nurmi Foundation
Dec 1993	Research Fellowship Paavo Nurmi Foundation
Dec 1995	Research Grant, Aarne Koskelo Foundation
Dec 1996	Research Grant, Aarne Koskelo Foundation
Aug 1997	Scientific Exchange Grant between the Netherlands and Finland, by NWO and the Finnish Academy together with PhD Gijsbert van Willigen and Prof Jan-Willem Akkerman, University Hospital of Utrecht
Dec 1997	Research Grant, Aarne Koskelo Foundation
Dec 1997	A visitor grant for PhD Johan Heemskerk, University of Limburg, the Netherlands, Maastricht, between Finnish Academy and NWO
April 2000	Grant by the Finnish Heart Research Foundation
Jan 2001	Helsinki University Hospital Governmental Grant, minor
Jan 2002	Helsinki University Hospital Governmental Grant, minor
Jan 2003	Helsinki University Hospital Governmental Grant, minor
Jan 2004	Helsinki University Hospital Governmental Grant, minor
Apr 2004	Grant by the Finnish Heart Research Foundation,
March 2005	Helsinki University Hospital Governmental Grant, minor
Jan 2007-11	Academy of Finland: Platelet-collagen interaction, basic mechanisms, clinical implications, development of inhibitors
Jan 2008	Helsinki University Hospital Governmental Grant, major
Jan 2012	Helsinki University Hospital Governmental Grant, minor
Jan 2013	Helsinki University Hospital Governmental Grant, minor
Sept 2014	Wihelm and Else Stockman foundation research grant
Jan 2015	Helsinki University Hospital Governmental Grant, major
<u>Awards</u>	
Sept 1988	Recipient of the 6th Department of Medicine Research Award, The Mount Sinai School of Medicine, New York
Nov 1989	Herman CB and Suzanne Denber Award for Cardiovascular Research, The Mount Sinai School of Medicine, New York
Feb 2015	Arosenius Lecture, in association with the 8 <sup>th</sup> Annual meeting of EAHAD

GCP training

In 2001 by Astra Zeneca, in 2009 by Wyeth

Professional Societies and memberships

Finnish Medical Association  
Societas Medicorum Fennica, Duodecim

The Ethical Committee of the Fourth Department of  
Surgery, Helsinki University Central Hospital 1996-1999.

Finnish Cardiac Society, Thrombosis Council, chairman 1998-  
2000, 2000-2003. Council member 2004-

Finnish Angiology Society, secretary 1996-2000. Council member 2000-  
chairman 2011-

American Heart Association, Council of Atherosclerosis,  
Thrombosis, and Vascular Biology, international fellow, 1997-

International Society of Thrombosis and Haemostasis, Scientific and  
Standardization Committee, and World Heart Federation, elected  
member of Council of Thrombosis 1998-2003.

Hemophilia Group, Finnish Society of Hematology, vice chair 2002-2005,  
chair 2005-07, 2007-member

Nordic haemophilia council, chair 2006-2007, 2007- member

American Society of Hematology, international fellow, 2003

American Society of Hematology, reviewer for the annual meeting 2005

European Haematology Association, reviewer for the meeting in 2006  
European Haematology Association, reviewer for the meeting in 2007

Board member of the Finnish Medical Agency (2008-2011)

European Haemophilia and Allied Disorders Surveillance System,  
EUHASS, steering committee 2008-2015

European Association of Haemophilia and Allied Disorders, steering  
committee, 2012-2015

European Haemophilia and Allied Disorders Network, EUHANET, steering  
committee 2012-2015

Reviewer:

Blood, Circulation, Arterioscler Thromb Vasc Biol, Thromb Haemost, J  
Thromb Haemost, Stroke, Blood Coagul Fibrinol, Am J Cardiol, Vox  
Sanguinis, Thromb Res, J Cardiovasc Pharmacol, Clin Chim Acta, Eur J  
Neurol, Ann Med, Acta Obst Gynecol, Ann Chir Gynaecol, Mech Ageing

Develop, Clin Physiol, Duodecim, Suomen Lääkärilehti, Crit Care Med, Brit Med J, Lancet

Swiss Academy of Sciences, 2002  
Austrian Academy of Sciences, 2004  
Irish Academy of Sciences, 2008  
Norwegian Academy of Sciences, 2009  
Swedish Research Council, 2011, 2012, 2013  
Belgian Academy of Sciences, 2010, 2012, 2015

Reviewer for 12 academic thesis (PhD):

1. Sari Väisänen: Associations of physical activity, fibrinogen genotypes and blood lipoproteins with thrombogenic factors in humans, University of Kuopio, Finland, 1997
2. Terhi Lehtinen: Integrin type collagen receptors as regulators of matrix related alterations in cell behaviour and gene expression, University of Turku, Finland, 1998
3. Marjukka Myllärniemi: Regulation of arterial smooth muscle cell proliferation after endothelial injury - an experimental approach to restenosis and transplant atherosclerosis, University of Helsinki, Finland 1999
4. Heikki Numminen, Actions of alcohol and ischaemic brain infarction. Department of Neurology, University of Oulu, Finland, 2000
5. Juha Horsti: Prothrombin time, evaluation of determination methods. Department of Clinical Chemistry, University of Tampere, Finland, 2002
6. Perttu Rossi: Eicosanoids and the pathophysiology of lower limb ischemia, Department of Vascular Surgery, University of Tampere, Finland, 2003
7. Marjut Salonvaara: Developmental Haemostasis in preterm infants and thrombotic complications during infancy, Department of Pediatrics, University of Kuopio, Finland 2004.
8. Elena Haapaniemi: Serial Changes in markers measuring coagulation, fibrinolysis and vasoactivity in patients with ischemic stroke, Department of Neurology, HUCH, University of Helsinki, Finland 2006.
9. Ari Rouhiainen: Role of HMGB1 in cells of the circulation. Neuroscience center, Division of Biochemistry, Faculty of Biosciences, Institute of Biotechnology, University of Helsinki, Finnish Red Cross Blood Transfusion Service, Finland, 2008
10. Outi Lindström: Inflammatory and coagulation disturbances in acute pancreatitis, Department of Gastric Surgery, HUCH, April 2010
11. Marko Sallialmi. Microcirculation and hemorheology in critically ill patients. Department of Surgery, Division of Anesthesia and Intensive Care Medicine, HUCH February 2012

12. Eeva-Maija Kinnunen. Bleeding complications and use of blood products in coronary artery bypass grafting. August 2015, University of Oulu

For two docent (associate professor) application:

Jari Petäjä, University of Helsinki, Medical Faculty, 1999

Karin Strandberg, University of Lund, Medical Faculty, Malmö, 2009

For six professor applications:

Michael Kroll, MD Andersson Clinics, Houston, Texas; USA 2008

Hans Deckmyn; University of Kortrijk, Belgium, 2009

Simon De Meyer, University of Leuven, Belgium, 2014

Maarit Venermo, University of Helsinki, Finland, 2014

Päivi Peltomäki, University of Helsinki, Finland, 2015

Anu Kantele, University of Helsinki, Finland, 2015

Supervisor for eleven thesis:

1. MD Seija Peltonen: "Implications of Blood Coagulation and Fibrinolysis Activation in Certain Cardiovascular Diseases", Faculty of Medicine, University of Helsinki, December 1997
  2. PhD Pia Siljander: "Platelet-collagen Interaction and Microvesiculation", Faculty of Biochemistry, University of Helsinki, March 2000
  3. MD Pirjo Mustonen: "Adrenaline and Arterial Thrombosis", Faculty of Medicine, University of Helsinki, February 2001
  4. MD Petteri Kauhanen: "Vascular regulation of hemostasis and fibrinolysis - with special focus on vein graft disease", Faculty of Medicine, University of Helsinki, April 2001. Joint supervision with Dr Mauri Lepäntalo.
  5. MD Eija Olsson: "Acute arterial thrombosis in microsurgery - clinical and experimental studies", Faculty of Medicine, University of Helsinki, December 2001. Awarded by the Finnish Society of Surgery as the thesis of the year. Joint supervision with Dr Sirpa Asko-Seljavaara.
  6. MD Eeva-Maija Hietala, "Poly-L, D-lactide stents as intravascular devices – an experimental study", University of Helsinki, Faculty of Medicine, June, 2004, Joint supervision with Dr Ari Harjula.
  7. MD Julio Resendiz: "Activation of PI3-kinase - a key regulator of platelet function", University of Helsinki, Faculty of Medicine, September 2005. Joint supervision with Dr Michael Kroll, Baylor College; Houston, Texas
  8. MD Sorella Ilveskero: "Procoagulant activity of adherent platelets", University of Helsinki, Faculty of Medicine, November 2005
  9. MD Aino Lepäntalo: "Individual variation in *in vitro* efficacy of antiplatelet medication – aspirin and clopidogrel", University of Helsinki, Faculty of Medicine, January 2007
  10. MD Peter Raivio: "Thrombin and its regulation in patients undergoing cardiac bypass surgery", University of Helsinki, Faculty of Medicine, December 2007, Joint supervision with Dr Jari Petäjä
  11. MD Birgitta Salmela: "Thrombophilia and direct thrombin inhibitor lepirudin – clinical and monitoring aspects", October 2010
- Currently six PhD students (Kaisa Vepsäläinen, Vuokko Jokela, Tuukka Helin, Hanna Pitkänen, Lauri Virtanen, Nora Varkila)

Opponent

1. Rijkshospitalet, Oslo, Norway, Sep 2006  
Andreas Dahm: TFPI and risk of venous thrombosis with mixed experimental and epidemiological studies
2. Faculty of Medicine, Katholieke Universiteit, Leuven, and Debrecen Hungary, Kortrijk, Belgium, Oct, 2007  
Timea Szanto: Modulation of the binding of von Willebrand factor to glycoprotein Ib or collagen by mutations and phage peptides.
3. Helsinki University, Faculty of Medicine, Dec 2007  
Kirsi Auro: Candidate gene studies on cardiovascular traits, Helsinki University.
4. Lund University, Malmö, Sweden, Faculty of Medicine, Oct 2008  
Else Lanke: Genetic characterization of families with Von Willebrand Disease
5. Faculty of Health Sciences, University of Copenhagen, Denmark, June 2011  
Marie Louise Schougaard Christiansen: Performance of functional coagulation assays in the development of new coagulation factor concentrates.
6. Faculty of Medicine, University of Linköping, Sweden, Nov 2011  
Martina Nylander: The role of platelet thrombin receptors PAR1 and PAR4 in health and disease.
7. Sahlgrenska, Gothenburg; Sweden, Nov 2013  
Vladimir Radulovic: Plasma coagulation in cardiac surgery.
8. Karolinska Institutet, Stockholm, Sweden, Sara Tehrani: Hemostasis and microvascular function in type 1 diabetes: effects of treatment with statin and aspirin. Jan 2014
9. Karolinska Institutet, Stockholm, Sweden, Ammar Majeed, Management of hemorrhagic complications associated with antithrombotic therapy, April 2014
10. Lund University, Department of Paediatrics Oct 2015. Annika Mårtensson. Haemophilia in Sweden: Studies on mutations and clinical implications.

Editor elected: Thrombosis Research, national editor, 2000-2,  
member of the editorial board 2003-  
Haemophilia 2002-  
The International Monitor of Haemophilia 2005-

Associate editor: Thrombosis Research, 2005-2014

Editor: Veritaudit, Text book of Hematology, 2007, eds Tapani Ruutu, Allan Rajamäki, **Riitta Lassila**, Kimmo Porkka, Duodecim, Finland.  
Veritaudit, Textbook of Hematology, 2014, Eds, Kimmo Porkka, Kari Remes, **Riitta Lassila**, Eeva-Maija Savolainen, Duodecim, Finland

Member for advisory boards: International meeting of International Society of Thrombosis and Haemostasis, ISTH  
ISTH, Paris 2001  
ISTH, Birmingham 2003  
ISTH, Sydney 2005  
ISTH, Geneva 2007

Hemapure, Uppsala, Sweden, 2001  
Astra Zeneca, Finland, 2001  
Aventis Pharma, Finland, 2001  
Annals of Medicine, 2002  
Nordic hemophilia council, 2002, chairperson 2005-  
European Haemophilia Therapy Standardisation Board/Baxter, 2003-2006  
Glaxo Smith Kline Beecham, International, 2004  
Expert in Internal Medicine, Coagulation Disorders, National Authority of Medicolegal Affairs, Finland (1.12.2004-30.11.2008, 1.12.2008-30.11.2013)

Invited expert for Agency of Medicines, Finland, from 2005-  
SanofiAventis, P6PP, 2005  
Advisory function in EMEA, London, UK, 2005-  
Wyeth European, 2007  
Board member, Finnish Medical Agency, Lääkelautakunta, 2008-  
Boehringer Ingelheim, Finland 2009  
Bayer, European AB 2010 -  
Pfizer, Finland 2010-  
Pfizer, haemophilia Europe, 2010 –

Patent application: PCT and US, 1998 and 1999, respectively and Aug 2014:

*Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions*

Patent application accepted in Australia 2003, accepted in Europe 2007, accepted in the USA in 2007 and amended in 2008.

*Therapeutic APAC*, filed in UK 26.8.2014

## Bibliography:

### 1. Original articles:

1. **Lassila R**, Lepäntalo M, Lindfors O. Peripheral arterial disease - natural outcome. *Acta Med Scand* 220:295-301, 1986.
2. **Lassila R**, Lepäntalo M. Cigarette smoking and the outcome after lower limb arterial surgery. *Acta Chir Scand* 154:635-40, 1988.
3. Laustiola K, **Lassila R**, Koskinen P, Pellinen T, Manninen. Gemfibrozil decreases platelet reactivity in patients with hypercholesterolemia during physical stress. *Clin Pharmacol Ther* 43:302-7, 1988.
4. **Lassila R**, Laustiola KE. Physical exercise provokes platelet desensitization in men who smoke cigarettes - involvement of sympathoadrenergic mechanisms - a study of monozygotic twin pairs discordant for smoking. *Thromb Res* 51:145-55, 1998.
5. Laustiola KE, **Lassila R**, Nurmi A-K. Enhanced activation of the renin-angiotensin-aldosterone system in chronic cigarette smokers - a study of monozygotic twin pairs discordant for smoking. *Clin Pharmacol Ther* 44:426-30, 1998.
6. **Lassila R**, Seyberth HW, Haapanen A, Schweer HW, Koskenvuo M, Laustiola KE. Vasoactive and atherogenic effects of cigarette smoking - a study of monozygotic twins discordant for smoking. *Br Med J* 297:955-7, 1988.
7. Laustiola KE, **Lassila R**, Kaprio J, Koskenvuo M. Decreased beta-adrenergic receptor density and catecholamine response in chronic cigarette smokers - a study of monozygotic twin pairs discordant for smoking. *Circulation*, 78:1234-40, 1988.
8. **Lassila R**. The alpha<sub>2</sub>-receptor and prostacyclin sensitivity of platelets are not altered by cigarette smoking - a study of monozygotic twin pairs discordant for smoking. *Thromb Res* 54:339-48, 1989.
9. **Lassila R**, Badimon JJ, Vallabhajosula S, Badimon L. Dynamic monitoring of platelet deposition on severely damaged vessel wall during blood flow. Effects of different stenoses on thrombus growth. *Arteriosclerosis*, 10:306-15, 1990.
10. Badimon L, Badimon J, **Lassila R**, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated fibrillar collagen type I at arterial flow conditions: Effects of hirudins, heparin and calcium chelation. *Blood*, 78:423-34, 1991.
11. Laustiola KE, Kotamäki M, **Lassila R**, Kallioniemi O-P, Manninen V. Cigarette smoking alters sympathoadrenal regulation by decreasing the number of beta adrenergic receptors. A study of monitored smoking cessation. *J Cardiovasc Pharmacol*, 17:923-8, 1991.
12. **Lassila R**, Lepäntalo M, Lindfors O. The efficacy of antiplatelet treatment with acetylsalicylic acid after lower limb arterial surgery with special reference to cigarette smoking. *World J Surgery*, 15:378-82, 1991.
13. **Lassila R**, Peltonen S, Lepäntalo M, Saarinen O, Kauhanen P, Manninen V. The severity of atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. *Arterioscler Thromb*, 13:1738-42, 1993.
14. Peräkylä TK, Lepäntalo M, **Lassila R**, Pietilä JA, Lindfors O. Working ability after arterial surgery for incapacitating chronic ischaemia of the lower limb. *Eur J Surg*, 160:425-9, 1994.
15. Peltonen S, **Lassila R**, Rossi P, Salenius J-P, Lepäntalo M. Blood coagulation and fibrinolysis activation during sudden arterial occlusion of lower extremities - an association with ischemia and patient outcome. *Thromb Haemost*, 74:1442-6, 1995.
16. Mustonen P, **Lassila R**. Epinephrine augments platelet recruitment to collagen in flowing blood - evidence for a von Willebrand factor -mediated mechanism. *Thromb Haemost*, 75:175-81, 1996.



17. Räikkönen K, **Lassila R**, Keltikangas-Järvinen L, Hautanen A. Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men - an interactive effect of serum insulin. *Arterioscler Thromb Vasc Biol*, 16:363-367, 1996.
18. Siljander P, Carpen O, **Lassila R**. Platelet-derived microparticles associate with fibrin during thrombosis. *Blood*, 87:4651-4663, 1996.
19. Peltonen S, **Lassila R**, Lepäntalo M. Patent peripheral venous bypass maintains fibrinolysis but markedly upregulates plasminogen activator inhibitor-1. *Thromb Res*, 82:369-377, 1996.
20. Peltonen S, **Lassila R**, Heikkilä J. Activation of coagulation and fibrinolysis despite heparinization during successful elective percutaneous transluminal coronary angioplasty. *Thromb Res*, 82:459-468, 1996.
21. Kauhanen P, Beer JH, **Lassila R**. Defective interaction between von Willebrand factor and platelet glycoprotein Ib in patients with peripheral arterial occlusive disease. *Thromb Haemost*, 77:849-855, 1997.
22. Pentikäinen M, Öörni K, **Lassila R**, Kovanen PT. Decorin links low density lipoproteins with collagen type I. *J Biol Chem*, 272:7633-7638, 1997.
23. Peltonen S, Juvela S, Kaste M, **Lassila R**. Hemostasis and fibrinolysis after subarachnoid hemorrhage. *J Neurosurg*, 87:207-214, 1997.
24. Kauhanen P, Siren V, Carpen O, Vaheri A, Lepäntalo M, **Lassila R**. Plasminogen activator-inhibitor 1 (PAI-1) in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure. *Circulation*, 96:1783-1789, 1997.
25. **Lassila R**, Lindstedt K, Kovanen PT. Native macromolecular heparin proteoglycans exocytosed from stimulated rat serosal mast cells strongly inhibit platelet-collagen interactions. *Arterioscler Thromb Vasc Biol*, 17:3578-87, 1997.
26. Mustonen P, Lepäntalo M, **Lassila R**. Exercise induces thrombin generation and fibrin degradation in patients with peripheral atherosclerosis. *Arterioscler Thromb Vasc Biol*, 18:244-9, 1998.
27. Kauhanen P, Kovanen PT, Reunala T, **Lassila R**. Effects of skin mast cells on bleeding time and coagulation activation at the site of platelet plug formation. *Thromb Haemost*, 79:843-7, 1998.
28. Wartiovaara U, Salven P, Mikkola H, **Lassila R**, Kaukonen J, Joukov V, Orpana A., Ristimäki A, Heikinheimo M, Joensuu H, Alitalo K, Palotie A. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. *Thromb Haemost*, 80:171-5, 1998.
29. Heemskerk J, Siljander P, Vuist WMJ, Breikers G, Reutelingsperger CPM, Barnes MJ, **Lassila R**, Farndale R. Function of glycoprotein VI and integrin  $\alpha 2\beta 1$  in the procoagulant response of collagen-bound platelets. *Thromb Haemost*, 81:782-792, 1999.
30. Badimon L, Martinez-Conzales J, Royo T, **Lassila R**, Badimon JJ. A surge of epinephrine transiently enhances platelet to platelet interaction to severely damaged arterial wall. Studies in a porcine model. *Thromb Haemost*, 82:1736-1742, 1999.
31. Siljander P, **Lassila R**. Studies of adhesion-dependent platelet activation: distinct roles for different participating receptors can be dissociated by proteolysis of collagen. *Arterioscler Thromb Vasc Biol*, 19:3033-3043, 1999.
32. Mustonen P, Savola J-M, **Lassila R**. Atipamezole, a specific  $\alpha 2$ -adrenoceptor inhibitor, binds to human platelets and inhibits their adrenaline-induced aggregation more effectively than yohimbine. *Thromb Res*, 99:231-237, 2000.
33. Wartiovaara U, Mikkola H, Szoke G, Haramura G, Karpati L, Balogh I, **Lassila R**, Muszbek L, Palotie A. Effect of Val134Leu on the activation of the coagulation factor XIII-A. *Thromb Haemost*, 84:595-600, 2000.
34. Olsson E, Sarlamo-Rikala M, Böhling T, Asko-Seljavaara S, **Lassila R**. Immunohistochemical evaluation of failed vessel anastomoses in clinical microsurgery. *Brit J Plastic Surg*, 53:567-573, 2000.
35. Kauhanen P, Kovanen PT, **Lassila R**. Collagen-immobilized native

- macromolecular heparin proteoglycans strongly inhibit platelet interactions under flowing blood. *Arterioscler Thromb Vasc Biol*, 20:e113-e119, 2000.
36. Ilveskero S, Siljander P, **Lassila R**. Soluble procoagulant activity upon platelets adhered to plasma clot or collagen. *Arterioscler Thromb Vasc Biol*, 21:628-635, 2001.
  37. Ihlberg LHM, Ahlbäck NA, **Lassila R**, Lepäntalo M. Intraoperative graft flow predicts the development of vein graft stenosis in infrainguinal arterial bypasses. *J Vasc Surg*, 34:269-276,2001.
  38. Olsson E, Svartling N, Asko-Seljavaara S, **Lassila R**. Activation of coagulation and fibrinolysis during reconstructive microsurgery in cancer. *Microsurgery*, 21:208-213, 2001.
  39. Lepäntalo A, Beer J, Siljander P, Syrjälä M, **Lassila R**. Variability of platelet responses to collagen - comparison between whole blood perfusion, traditional platelet function tests and PFA-100. *Thromb Res*, 103:123-133, 2001.
  40. Olsson E, Svartling N, Asko-Seljavaara S, **Lassila R**. Activation of coagulation and fibrinolysis in microsurgical reconstructions in lower extremities. *Br J Plast Surg*, 54:597-603,2001.
  41. Mustonen P, van Willigen G, **Lassila R**. Epinephrine - via activation of P38-Mapk - abolishes the effect of aspirin on platelet deposition to collagen. *Thromb Res*, 104:439-449,2001.
  42. Puurunen M, Palosuo T, **Lassila R**, Anttila M, Vaarala O. Immunologic and hematologic properties of antibodies to prothrombin and plasminogen in a mouse model. *Lupus*, 10:108-115,2001.
  43. Westerbacka J, Yki-Järvinen H, Turpeinen A, Rissanen A, Vehkavaara S, Syrjälä M, **Lassila R**. Inhibition of platelet-collagen interaction: a normal in vivo action of insulin abolished by obesity. *Arterioscler Thromb Vasc Biol*, 22:167-172,2002.
  44. Olsson E, Asko-Seljavaara S, **Lassila R**. Topically administered macromolecular heparin proteoglycans effectively inhibit thrombus growth in microvascular anastomoses. *Thromb Haemost*, 87;245-51,2002.
  45. Pontiggia L, **Lassila R**, Pederiva S, Schmid HR, Burger M, Beer JH. Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphisms of platelet GPIa and GPIIIa. *Arterioscler Thromb Vasc Biol*, 22:2093-2098, 2002.
  46. Ilveskero S, **Lassila R**. Abciximab, a glycoprotein IIb/IIIa antagonist, inhibits procoagulant activity but not release reaction, upon collagen- or clot-adherent platelets. *J Thromb Haemost*, 805-813, 2003.
  47. Siren V, Kauhanen P, Luther M, Carpen O, Vaheri A, Lepäntalo M, **Lassila R**. Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts. *Blood Coagul Fibrinol*, 14:369-377, 2003.
  48. Tamminen M, **Lassila R**, Westerbacka JJ, Vehkavaara SS, Yki-Järvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in non-diabetic subjects. *Internat J Obes Relat Metab Disord* 27;907-11, 2003.
  49. Nuotio K, Lindsberg P, Carpen O, Soenne L, Lehtonen-Smeds EMP, Saimanen E, **Lassila R**, Sairanen T, Sarna S, Salonen O, Kovanen PT, Kaste M. Adhesion molecule expression in symptomatic and asymptomatic carotid stenosis. *Neurology*, 60:1890-1899, 2003.
  50. Ylikorkala O, Cacciatore C, Halonen K, **Lassila R**, Lammintausta R, Rutanen E-M, Heikkinen J, Komi J. Effects of ospemifene, a novel serm, vascular markers and function in healthy postmenopausal women. *Menopause* 10:440-447, 2003.
  51. Hietala E-M, Maasilta P, Välimaa T, Harjula AL, Törmälä P, Seppälä J, **Lassila R**. Polylactide and heparin-coated polylactide as stent materials - studies on platelet deposition and coagulation activation in vitro, *J Biomat Med Res*, 67A:785-791, 2003.
  52. Siironen J, Juvela S, Varis J, Porras M, Poussa K, Ilveskero S, Hernesniemi J, **Lassila R**. No effect of enoxaparin on the outcome of aneurysmal subarachnoid

hemorrhage: a randomised double-blind placebo-controlled clinical trial. *J Neurosurg*, 99:953-959, 2003.

53. Schulman S, Wåhlander K, Lundström T, Billing Classon S, Eriksson H for the **Thrive Investigators**. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor Ximelagatran. *N Engl J Med* 1713-1721, 2003

54. Lepäntalo A, Virtanen K, Heikkilä J, Wartiovaara U, **Lassila R**. Limited antiplatelet effect of combined ASA and Clopidogrel in patients undergoing elective PTCA *Eur Heart J*, 25:476-83. 2004. Followed by an editorial: 454-6.

55. Hietala E-M, Maasilta P, Juuti H, Nuutinen JP, Harjula ALH, Salminen US, **Lassila R**. Platelet deposition on stainless steel, spiral and braided polylactide stents: a comparative study. *Thromb Haemost*, 92:1394-1401, 2004.

56. Lehtonen-Smeds E, Mäyränpää M, Lindsberg P, Soinne L, Saimanen E, Järvinen AJ, Salonen O, Carpen O, **Lassila R**, Sarna S, Kaste M, Kovanen PT: Carotid plaque mast cells associate with atherogenic serum lipids, high grade carotid stenosis and symptomatic carotid artery disease. *Cerebrovasc Dis* 19:291-301, 2005.

57. Ilveskero S, Juvela S, Siironen J, **Lassila R**. D-dimer predicts outcome after subarachnoidal haemorrhage – no effect of thromboprophylaxis on coagulation activity. *Neurosurgery*, 57:16-24, 2005.

58. Soinne L, Saimanen E, Malmberg-Ceder K, Kovanen P, Lindsberg PJ, Kaste M, **Lassila R**. Association of fibrinolytic system and hemorheology with symptoms in patients with carotid occlusive disease. *Cerebrovasc Dis*, 20:172-179, 2005.

59. Ilveskero S, **Lassila R**. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists. *Thromb Res* 117:291-297, 2006.

60. Puurunen M, **Lassila R**. Successful treatment of mesenteric venous thrombosis with lepirudin – a report of five cases. *Thromb Res*, 118:241-245, 2006.

61. Lepäntalo A, Mikkelsen J, Resendiz JC, Heinonen L, Karhunen PJ, **Lassila R**. Genetic variation in COX-1 associates with the antiplatelet effect of aspirin in coronary artery disease. *Thromb Haemost*, 95:253-259, 2006.

62. Raivio P, Kuitunen A, Suojaranta-Ylinen R, **Lassila R**, Petäjä J. Thrombin generation during reperfusion after coronary bypass surgery associates with postoperative myocardial damage. *J Thromb Haemost*, 4:1523-9, 2006.

63. Kuitunen A, Suojaranta-Ylinen R, Raivio P, Kukkonen S, **Lassila R**. Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome. *J Cardiothorac Vasc Anesth*, 21:18-22, 2007.

64. Raivio P, Fernandez J, Kuitunen A, Griffin J, **Lassila R**, Petäjä J. Activation of Protein C and Hemodynamic Recovery After Coronary Artery Bypass Surgery. *J Thorac Cardiovasc Surg*, 133:44-51, 2007.

65. Aho PS, Niemi T, Piilonen A, **Lassila R**, Renkonen R, Lepäntalo M. Interplay between coagulation and inflammation in open and endovascular abdominal aortic aneurysm repair- impact of intra-aneurysmal thrombus. *Scand J Surg*. 96:229-35, 2007.

66. Szanto T, Salmela B, Mäkipernaa A, Armstrong E, **Lassila R**. Management of acute myocardial infarction in a patient with Factor XIII deficiency using prophylactic factor replacement therapy. Case report. *Haemophilia*, 14:163-5, 2007.

67. Ludvigsson JF, Welander A, **Lassila R**, Ekblom A, Montgomery SM. Risk of thromboembolism in 14 000 individuals with celiac disease. *Brit J Haematol*, 139:121-127, 2007.

68. Salmela B, Nordin A, Vuoristo M, Mäkisalo H, Numminen K, **Lassila R**. Budd-Chiari syndrome in a young female with aPC resistance – treatment with a direct thrombin inhibitor lepirudin. Brief communication. *Thromb Res*, 121:769-72, 2007

69. Resendiz J, Kroll M, **Lassila R**. Protease activated receptors-induced Akt activation – regulation and possible function. *J Thromb Haemost* 5:2484-2493, 2007.

70. Raivio P, Petäjä J, Kuitunen A, Fernandez JA, Eriksson H, Griffin JH, **Lassila R**. Thrombophilic variables do not increase the generation or procoagulant activity of thrombin during cardiopulmonary bypass. *Ann Thorac Surg*, 85:536-42, 2008. Followed by editorial, RW Colman.
71. Jalanko H, Peltonen S, Koskinen A, Puntilla J, Isoniemi H, Holmberg C, Pinomäki A, Armstrong E, Koivusalo A, Tukiainen E, Mäkisalo H, Saland J, Remuzzi G, de Gordoba S, **Lassila R**, Meri S, Jokiranta S. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. *Am J Transplant*, 8:216-21, 2008.
72. Raivio P, Kuitunen A, Petäjä J, Ilveskero S, **Lassila R**. Monitoring high-dose heparinisation during cardiopulmonary by-pass – a comparison between Prothrombinase-induced Clotting Time (PiCT) and two chromogenic anti-factor Xa activity assays. *Thromb Haemost*, 99:427-34, 2008.
73. Forestier M, Pontiggia L, Resendiz J, **Lassila R**, Beer JH. Platelet microparticle suppressing antibody against GPIIb/IIIa acts independently of the filamin cleavage and increases protein tyrosine phosphorylation. *Blood Coag Fibrinol*, 19:801-6, 2008
74. Jartti L, Rönnemaa T, Raitakari OT, Hedlund E, Hammar N, **Lassila R**, Marniemi J, Koskenvuo M, Kaprio J. Migration at early age from a high to a lower coronary heart disease risk country lowers the risk of subclinical atherosclerosis in middle-aged men. *J Intern Med*, 265:345-58, 2009
75. Haapaniemi E, Helenius J, Jakovljevic D, Syrjälä M, Kaste M, **Lassila R**, Tatlisumak T. Ischemic stroke patients with heterozygous Factor V Leiden present with multiple brain infarctions and widespread atherothrombotic disease. *Thromb Haemost*, 101:145-50, 2009
76. Salmela B, Albäck A, Räike P, Lepäntalo M, **Lassila R**. Direct thrombin inhibitor, lepirudin, for thrombophilic patients with inoperable severe leg ischemia. *Thromb Res*, 123:719-723, 2009
77. Lepäntalo A, Virtanen KS, Resendiz J, Mikkelsson J, **Lassila R**. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions - limited inhibition of the P2Y12 receptor. *Thromb Res*, 124:193-198, 2009
78. Pinomäki A, Volin L, Joutsu-Korhonen L, Virtanen JO, Lemponen M, Ruutu T, **Lassila R**. Early thrombin generation and impaired fibrinolysis after stem cell transplantation associate with acute graft-versus-host-disease. *Bone Marrow Transplant*, 45:730-7, 2009
79. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators. Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 361:1045-5, 2009
80. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 361:1139-51, 2009
81. Saarela M, Tiitola M, Lappalainen K, Vikatmaa P, Pinomäki A, Alberty A, **Lassila R**. A pseudoaneurysm formation in a haemophilia A. *Haemophilia*, 16:686-8, 2010

82. Nissinen L, Pentikäinen OT, Jouppila A, Käpylä J, Ojala M, Lehtisalo J, Johnson MS, **Lassila R**, Marjamäki A, Heino J. A small molecule inhibitor of integrin  $\alpha 2\beta 1$  introduces a new strategy for antithrombotic therapy. *Thromb Haemost*, 103:387-97, 2010
83. Salmela B, Joutsu-Korhonen L, **Lassila R**. Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant, *Thromb Res*, 125:538-44, 2010
84. Laine O, Mäkelä S, Mustonen J, Huhtala H, Szanto T, Vaheri A, **Lassila R**, Joutsu-Korhonen L. Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection. *Thromb Res* 126:154-8, 2010
85. Raivio PM, **Lassila R**, Kuitunen AH, Eriksson H, Suojaranta-Ylinen RT, Petäjä J. Increased preoperative thrombin generation and low protein S level associate with unfavourable postoperative hemodynamics after coronary artery bypass grafting, *Perfusion*, 26:99-106, 2010
86. Kotronen A, Joutsu-Korhonen L, Sevastionova K, Bergholm R, Hakkarainen A, Pietiläinen KH, Lundholm A, Rissanen A, **Lassila R**, Yki-Järvinen H. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease, *Liver Int*, 31:176-83, 2011
87. Wartiovaara-Kautto U, Ilveskero S, Joutsu-Korhonen L, Armstrong EA, **Lassila R**. Significant distinction between plasma- and platelet-associated coagulation activities in haemophilia A *Haemophilia*, 17:743-51, 2011
88. Laine O, Mäkelä S, Mustonen J, Helminen M, Vaheri A, **Lassila R**, Joutsu-Korhonen L. Platelet ligands and ADAMTS13 during Puumala hantavirus infection and associated thrombocytopenia. *Blood Coag Fibrinol*, 22:468-72, 2011
89. Mäntysaari M. Joutsu-Korhonen L, Siimes MA, Siitonen S, Parkkola K, Lemponen M, **Lassila R**. Unaltered blood coagulation and platelet function in healthy subjects exposed to hypoxia. *Aviation Space Environmental Med*, 22:696-703, 2011
90. Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, Jo H, Kavakli K, **Lassila R**, Morfini M, Négrier C, Rocino A, Schramm W, Serban M, Uscatescu MV, Windyga J, Zulfikar B. A prospective, randomized, crossover study of anti-inhibitor coagulant complex for bleeding prophylaxis in patients with hemophilia A and inhibitors: results of the Pro-FEIBA study, *N Engl J Med*, 365:1684-1692, 2011
91. Richard C. Becker, Jean Pierre Bassand, Andrzej Budaj, Daniel M. Wojdyla, Stefan K. James Jan H. Cornel, John French, Claes Held, Jay Horrow, Steen Husted, Jose Lopez-Sendon, **Riitta Lassila**, Kenneth W. Mahaffey, Robert F. Storey, Robert A Harrington, Lars Wallentin. Bleeding Complications with the P<sub>2</sub>Y<sub>12</sub> Receptor Antagonists Clopidogrel and Ticagrelor in the PLATElet Inhibition and Patient Outcomes (PLATO) Trial. *Eur Heart J* 32:2933-2944, 2011
92. Kaye S, Pietiläinen K, Kotronen A, Joutsu-Korhonen L, Kaprio J, Yki-Järvinen H, Silveira A, Hamsten A, **Lassila R**, Rissanen A. Obesity-related derangements of coagulation and fibrinolysis: a study of obesity-discordant monozygotic twin pairs. *Obesity* 20:88-94, 2012

93. Pöyhönen-Alho M, Joutsu-Korhonen L, **Lassila R**, Saarinen A, Kaaja R. Alterations of sympathetic nervous system and platelet function in gestational diabetes in coagulation variables. *Blood Coag Fibrinol* 23:508-13; 2012
94. Holmberg T, Joutsu-Korhonen L, Neuvonen P, Niemi M, **Lassila R**, Backman J. Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. *Brit J Clin Pharmacol*, 75:1488-96, 2013
95. Salmela B, Hartman J, Peltonen S, Albäck A, **Lassila R**. Thrombophilia and Vascular Access Survival in End-Stage Renal Disease. *Clin J Am Soc Nephrol*, 8:962-8, 2013
96. Helin T, Pakkanen A, **Lassila R**, Joutsu-Korhonen L. Laboratory assessment of novel oral anticoagulants: Method suitability and variability between coagulation laboratories. *Clin Chem*, 59:807-14, 2013.
97. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; **MAGELLAN Investigators**. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. *N Engl J Med*. 2013;368:513-23.
98. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvanme AM, Friedman J, Mismetti P, Goldhaber SZ; **RE-MEDY Trial Investigators**; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. *N Engl J Med*. 368:709-18,2013
99. Jokela V, **Lassila R**, Szanto T, Joutsu-Korhonen L, Armstrong E, Oyen F, Schneppenheim S, Schneppenheim R. Phenotypic and genotypic characterization of 10 Finnish patients with von Willebrand disease type 3: discovery of two main mutations. *Haemophilia*, 2013, 9:e344-8.
100. Säily VM, Pétaš A, Joutsu-Korhonen L, Taari K, **Lassila R**, Rannikko AS. Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: Retrospective analysis of safety profile and effect on blood coagulation. *Scan J Urol* 2014, 48:153-9.
101. Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, Himmelmann A, Horrow J, Katus HA, **Lassila R**, Morais J, Nicolau JC, Steg G, Storey RF, Wojdyla D, Wallentin L for the PLATO study group. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. *Eur Heart J*, 2014;35:1541-50.
102. Virtanen L, Salmela B, Leinonen J, Lemponen M, Huhtala J, Joutsu-Korhonen L, **Lassila R**. Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement. *Blood Coagul Fibrinolysis*. 2014, 25:597-603
103. **Lassila R**, Jouppila A. Mast-cell heparin proteoglycans as a model for a local antithrombotic. *Semin Thromb Hemostas* 2014;40:837-44.
104. Ducrocq G, Schulte PJ, Becker RC, Cannon CP, Harrington RA, Held C, Himmelmann A, **Lassila R**, Storey RF, Sorbets E, Wallentin L, Steg PG, Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial, *Eurointervention*, 2014, in press.
105. Salmela A, Ekstrand A, Joutsu-Korhonen L, Räisänen-Sokolowski A, **Lassila R**. Activation of endothelium, coagulation and fibrinolysis is enhanced and associates with

renal ANCA associated vasculitis. *Nephrology Dialysis Transplantation*, 2015;suppl 1:53-69.

106. **Lassila R**, Jula A, Pitkäniemi J, Haukka J. Statin use associates with reduced incidence of venous thromboembolism – a nationwide population-based cohort study. *BMJ Open*, 2014;4:e005862.

107. Pitkänen H, Jouppila A, Mowinckel M-C, Lemponen M, Patiwaël S, Per Morten Sandset PM, **Lassila R**, and Brinkman H-JM. Enhanced thrombin generation and reduced tissue factor pathway inhibitor and intact protein S in processed solvent detergent plasma. *Thromb Res* 2015;135:167-74.

108. Rikala M, Hauta-aho M, Helin-Salmivaara A, **Lassila R**, Korhonen MJ, Huupponen R. Potential drug interactions during warfarin therapy – a population-based register study, *Basic Clin Pharm Tox*, 2015, 117:126-32.

109. Sivula M, Hästbacka J, Kuitunen A, **Lassila R**, Tervahartiala T, Sorsa T, Pettilä V. Systemic matrix metalloproteinase-8 and tissue inhibitor of metalloproteinases-1 levels in severe sepsis associated coagulopathy. *Acta Anaesthesiol Scand* 2015;59:176-84

110. Fischer K, **Lassila R**, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M, on behalf of the EUHASS participants. Inhibitor development in haemophilia according to concentrate: Four-year results from the European Haemophilia Safety Surveillance (EUHASS) project. *Thromb Haemost* 2015;113:968-75.

111. Vepsäläinen K, **Lassila R**, Arola M, Lähteenmäki P, Möttönen M, Mäkipernaa A, Riikonen P. Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland. *Haemophilia* 2015;21:747-53.

112. Helin T, Lemponen M, Rönquist-Ni Y, Hjemdahl P, **Lassila R**, Joutsu-Korhonen L. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples. *Thromb Res* 2015, 136: 154-60.

113. Laine O, Joutsu-Korhonen L, **Lassila R**, Koski T, Huhtala H, Vaheri A, Mäkelä S, Jukka Mustonen J. Hantavirus infection-induced thrombocytopenia associates with impaired platelet aggregation but increases platelet production and secures platelet deposition under blood flow, *Thromb Res*, 2015; 136:1126-32.

114. Jokela, V, Jouppila A, **Lassila R**. High dose recombinant factor IX prophylaxis maintains FIX activity and thrombin generation at trough upon once weekly administration. *Haemophilia*, submitted 2016

115. Pitkänen HH, Jouppila A, Lemponen M, Ilmakunnas M, Ahonen J, **Lassila R**. FXIII deficiency reduces fibrinogen function but enhances thrombin generation due to impaired fibrin polymerisation - an effect corrected by FXIII replacement. *Haemophilia*, to be submitted

116. Virtanen L, Jouppila A, Joutsu-Korhonen L, Lemponen M, van Wijngaarden A, Vos H, **Lassila R**. Solvent-detergent plasma abolished severe bleeding tendency and normalized procoagulant activity both in plasma and platelets of a FV deficient patient, to be submitted

117. Ratasvuori M, **Lassila R**, Laitinen M. Venous Thromboembolism after Surgical Treatment of Non-Spinal Skeletal Metastases– An Underdiagnosed Complication.

Thromb Res, resubmitted 2015

118. Vepsäläinen K, **Lassila R**, Arola M, Möttönen M, Huttunen P, Lähteenmäki P, Ljung R, Riikonen P. Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicenter study in Finland. Haemophilia, submitted 2016

## 2. Review articles

1. **Lassila R**. The Thrombogenic and Vasoactive Mechanisms of Cigarette Smoking with Special Reference to Peripheral Arterial Disease. Academic Thesis, the Medical Faculty in the University of Helsinki, 1989.
2. Badimon L, Badimon JJ, **Lassila R**, Turitto VT, Fuster V. Thrombosis on stenosis: mechanisms of thrombus growth and embolization on carotid atherosclerotic plaques. In: Cerebral ischaemia and calcium. Eds. Hartmann A & Kuschinsky W. Springer Verlag, N.Y., p. 314-322, 1989.
3. **Lassila R**. Äkillinen valtimotromboosi ja verihiutaleet - tutkimuksen nykynäkymiä. Acute arterial thrombosis and platelets - the current research approaches. Duodecim 1990;106:970-7.
4. **Lassila R**, Koskenvuo M, Kaprio J, Laustiola KE. Valtimonseinämän ja verihiutaleiden vuorovaikutus tupakoitsijoilla. The interaction between arterial wall and platelets in cigarette smokers. Suomen Lääkärilehti, 1990;3:135-9.
5. Lepäntalo M & **Lassila R**. Smoking and occlusive peripheral arterial disease (a review). Eur J Surg 1991;157:83-7.
6. **Lassila R**. Hirudiini - iilimadon uusi tuleminen. Hirudin - a return of the old leech (editorial). Duodecim, 108:535-7, 1992.
7. **Lassila R**. The thrombogenic and vasoactive effects cigarette smoking - with special reference to peripheral arterial disease. Ann Chir Gynaecol, 81:107-9, 1992.
8. **Lassila R** & Laustiola KE. Cigarette smoking and platelet-vessel wall interaction. Prostaglandin Leukotriene Ess Fatty Acids 46, 81-86, 1992.
9. **Lassila R** & Laustiola KE. Cigarette smoking and peripheral arterial occlusive disease - evidence for adrenergic connections. J Smoking-Related Dis, 3: 217-23, 1992.
10. Peuhkurinen K, **Lassila R**. Mitä sydäninfarktin trombolyyttisen hoidon jälkeen? The adjuvant medication after thrombolytic therapy for acute myocardial infarction. Lääkeuutiset, 3:20-24, 1992.
11. **Lassila R**. Inflammation in atheroma: implications for plaque rupture and platelet-collagen interaction. Eur Heart J, 14, suppl K, 94-97, 1993.
12. Jang I. K, **Lassila R**, Fuster V. Atherogenesis and inflammation. Eur Heart J, 14, suppl K, 2-6, 1993.
13. **Lassila R**, Manninen V. Hypofibrinolysis and increased lipoprotein(a) coincide in stroke. Editorial. J Clin Lab Med, 125:301-2, 1995.
14. **Lassila R**. Antitromboottiset lääkkeet. Current antithrombotic drugs. Finnanest, 1998.
15. **Lassila R**. Epästabiilin angina pectoriksen antitromboottinen lääkehoito. (Current treatment of unstable angina pectoris). Editorial. Duodecim, 1998, 114:1441-4.
16. Petri T Kovanen, **Riitta Lassila**. Update of pathophysiology of acute coronary syndromes. Acute coronary syndromes (A.C.S). IBC Global Conferences, Paris, December, 1998
17. Kovanen PT, Carpen O, **Lassila R** and Kaste M. Carotid plaques and stenosis: molecular mechanisms affecting the development of symptomatic



lesions. In: Prevention of Ischemic Stroke, eds. Cesare Fieschi and Marc Fisher, Martin Dunitz Ltd publisher, p.193-216, 1999.

18. **Lassila R.** Tarvitsevatko kaikki aikuistyyppin diabeetikot aspiriinia? (Article in Finnish, Aspirin to all adult-onset diabetics?). Duodecim, 10,1174-7, 1999.

19. **Lassila R.** D-dimeerin merkitys diagnostiikassa. Editorial. (Article in Finnish, The diagnostic role of D-dimer) Duodecim, 115:2707-9, 1999.

20. **Lassila R** and Kovanen PT. Pathophysiology of arterial thrombosis. (Article in Finnish: Valtimotromboosin patofysiologia) In: Kardiologia. Heikkilä, Peuhkurinen, Luomanmäki, eds. Duodecim, 461-72, 2000.

21. **Lassila R.** Blood coagulation and fibrinolysis (Article in Finnish: Veren hyytyminen ja fibrinolyysi). In: Veritaudit, Ruutu, Krusius and Rajamäki, eds. Duodecim 2000.

22. Ilveskero S, Joutsi-Korhonen L, Javela K, **Lassila R.** HIT- hepariinin indusoima trombosytopenia. Suomen Lääkärilehti, 42:42, 2000.

23. Halinen M, **Lassila R.** Tekoläppäpotilaan antikoagulanttihoito. (Article in Finnish, The anticoagulant treatment in patients having artificial heart valves). Duodecim, 116:157-165, 2000.

24. **Lassila R**, Manninen V. Preface to the Proceedings of the XIII Paavo Nurmi Symposium - Arterial Thrombosis -from Mechanisms to Treatment, Ann Med 32 suppl I:1, 2000.

25. **Lassila R.** Akuuttihoito-opas (Acute care medicine). Antikoagulanttihoito leikkausten ja toimenpiteiden yhteydessä (Anticoagulation therapy in association with operations and invasive diagnostic procedures). 332-36, 2001

26. **Lassila R**, Pietilä K, Pentikäinen PJ. Antitromboottinen lääkehoito. Kliininen Farmakologia (Antithrombotic treatment, Clinical Pharmacology) 2002.

27. **Lassila R.** Tukos varfariinista huolimatta - mikä avuksi? (Thrombosis despite warfarin – what to do?) Duodecim, 117:2632-6;2001

28. **Lassila R**, Leinonen H. Tarvitaanko vielä fraktiomatonta hepariinia? (Do we still need unfractionated heparin?) Editorial, Duodecim 117:2597-9;2001.

29. Räike P, Anttila P, Railo M, Lepäntalo M, **Lassila R.** Trombofilia ja vaikea valtimotromboosi (Thrombophilia and difficult arterial thrombosis). Duodecim, 119:881-885, 2003.

30. Räike P, Alback A, Lepäntalo M, **Lassila R.** Aterotrombos - patofysiologi och vård. (Pathophysiology and treatment of atherothrombosis). Finska Läkaresällskapet Handlingar, 163:14-8;2003.

31. Karhapää P, Kaukanen E, Koivula I, **Lassila R.** Alaonttolaskimon anomalia ja laskimotromboosi nuorella miehellä. Tapausselostus. (Thrombosis of anomalous vena cava. A case report). Duodecim, 120:402-7;2004.

32. Rossinen J, **Lassila R**, Nieminen MS. Liuotushoito ja siihen liittyvän vuotoriskin hallinta akuutissa sydäninfarktissa. (Fibrinolytic therapy and management of increased bleeding risk) Suomen Lääkärilehti, 7:635-41;2004.

33. **Lassila R**, Halinen M, Harjola V-P, Kunnamo I, Melin J, Mustonen P, Pohjola-Sintonen S, Sinisalo J, Teittinen J. Käypä Hoito; Syvä laskimotukos ja keuhkoembolia, (Consensus guidelines, Treatment and prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism) Duodecim, 120:1028-45, 2004

34. **Lassila R.** D-dimeeri - klinikon pelastus vai päänsärky? Duodecim, pääkirjoitus. (D-dimer: whether this test helps or disturbs the clinician, Editorial). Duodecim, 120:1057-8; 2004.

35. Niemi T, **Lassila R.** Leikkauspotilaan antitromboottinen hoito. (Antithrombotic therapy and surgery) Duodecim, 120:1325-32;2004.

36. **Lassila R.** Suurentunut D-dimeeriarvo – klinikon haaste. Pääkirjoitus, (Elevated D-dimer – a challenge for a clinician, editorial). Suomen Lääkärilehti, 24:2475;2004.

37. **Lassila R.** Leikkauspotilaan hemostaasi. (Hemostasis of a surgical patient). Leiraksen Käytännön Lääkäri:47:10-14; 2004.

38. Rossinen J, Viita J, Nieminen MS, **Lassila R**. Uhkaavan transmuraalisen sydäninfarktin hoitoon liittyvät vuotokomplikaatiot (Clinical determinant of severe bleeding complications in patients having acute myocardial infarction treated with thrombolytic therapy) Suomen Lääkärilehti 11:1263-1267; 2005.
39. **Lassila R**. Basic mechanisms, acquired and genetic defects associated with thrombosis. In: Pathology&Genetics Cerebrovascular Diseases, Kalimo HISN Neuropath Press, Basel pp.58-61, 2005.
40. **Lassila R**. Ksimelagatraani – uusi trombiinin estäjä, (Ximelagatran – a new thrombin inhibitor). Therapia, 2004
41. **Lassila R**. Hemostaasi. (Haemostasis). Patologian oppikirja, 2006 (Finnish Textbook of Pathology)
42. **Lassila R**, Rothschild C, de Moerloose P, Richards M, Perez R, Gajek H. Recommendations for post-marketing surveillance studies in Haemophilia and other bleeding disorders. Haemophilia, 11;353-359, 2005.
43. **Lassila R**. Aterotromboosin synty – trombologin näkökulma. (Initiation of atherothrombosis – the vision of a “thrombologist”,iIn) Angiologia, Pertti Aarnio et al, editors, Recallmed: s. 8-16;2005.
- 44 **Lassila R**. Antitromboottinen hoito. (Antithrombotic therapy) Angiologia, Pertti Aarnio et al., editors, Recallmed; s.28-45; 2005.
45. Lepäntalo M, Vuorisalo Sailaritta, **Lassila R**. Unexpected causes of acute lower limb ischemia, In: Unexpected Challenges in Vascular Surgery, eds. Alain Branchereau and Michael Jacobs, Malden, Mass, Blackwell Futura, ISBN 1-4051-3470-4, p. 185-94, 2005
46. **Lassila R**. Cardiovascular morbidity in hemophilia. Int Monitor Hemophilia, 2005
47. **Lassila R**. Thrombin Generation and Hemophilia A. Int Monitor Hemophilia, 2006;14:39-40.
48. **Lassila R**. Veren hyytyminen ja fibrinolyysi. (Blood coagulation and fibrinolysis). Veritaudit oppikirja, 2006 (Finnish Textbook: Diseases of Blood), s. 32-44, 2006.
49. Mustonen P, **Lassila R**. Antitromboottiset ja fibrinolyttiset lääkkeet.(Antithrombotic and fibrinolytic therapy). Veritaudit oppikirja, s. 596-611;2006
50. Rasi V, Siimes M, Lassila R. Hemofilia (Haemophilia). Veritaudit oppikirja, s. 516-531; 2006
51. **Lassila R**. Chromogenic assay modified for very low levels of factor VIII. Int Monitor Hemophilia 2006;14:17.
52. Kaste M, Sairanen T, Häppölä O, **Lassila R**, Lepäntalo M, Lindsberg PJ, Lohi J, Pesonen H, Pohjasvaara T, Poutiainen E, Rissanen A, Roine RO, Sivenius J, Strandberg T, Syväne M, Turkka J. Käypä hoito suositus – Aivoinfarkti. (Guidelines in the treatment of Ischemic Stroke). Duodecim 2006;122:2770- 2790.
53. **Lassila R**. Syöpä ja tromboosi. (Cancer and thrombosis). Suomen Lääkärilehti, (Finnish Medical Journal), 7:619-625;2007. Pääkirjoitus (Editorial by) Pirjo Koistinen: 2007,7:617.
54. **Lassila R**. Laskimotukos ja Keuhkoembolia. (Deep vein thrombosis and pulmonary emboli, Finnish textbook of Traumatology) In: Traumatologia. Toim, Hannu Aro 2007
55. Halinen M, **Lassila R**. Pitkäaikainen antikoagulaatiohoito: käytön aiheet, toteutus ja menettely erityistilanteissa. (Long-term anticoagulation: indications, execution and application under special conditions), Kardiologian oppikirja, (Finnish Textbook of Cardiology), 2007
56. Richards M, Altisent C, Batorova A, Chambost H, Dolan G; de Moerloose P, Fraga M, Hermans C, Karafoulidou A, Klamroth R, **Lassila R**, Rothshild C on behalf of the European Haemophilia Therapy Standardisation Board. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? A survey of practice across Europe. Haemophilia, 13: 473-479;2007.

57. **Lassila R**, Mäkipernaa A. Lyhyttä vai pitkää hepariiniaketjua tukospotilaalle? Short or long chains of heparin for treatment of thrombosis. Editorial, Duodecim, 123: 2925-2927, 2007.
58. Poikonen E, Armstrong E, Salo J, **Lassila R**. Hankinnainen vuotoalttius ja toimenpiteisiin valmistautuminen. Acquired bleeding tendency and preparation for surgery. Suomen Lääkärilehti, 44:4111-4114, 2007.
59. **Lassila R**. Recombinant FVIIa analog and whole blood clot formation. International Monitor of Haemophilia, 15:25,2007
60. **Riitta Lassila**. Measuring primary haemostasis. Klinisk Biokemi i Norden. Supplementsudgave – Koagulation. P 10-13; 2007.
61. Colvin BT, Astermark J, Fischer K, Gringeri A, **Lassila R**, Schramm W, Thomas A, Ingerslev J; FOR THE INTERDISCIPLINARY WORKING GROUP. European principles of haemophilia care. Haemophilia. 14:361-74; 2008.
62. Janne Backman, Lotta Joutsu-Korhonen, Pertti Neuvonen, **Riitta Lassila**. CYP2C9 ja VKORC1 -geenitestit aouna oraalisen antikoagulanttihoidon toteuttamisessa (CYP2C9 and VKORC1 genetic testing in the management of oral anticoagulation) Duodecim, 124:1283-8, 2008.
63. **Lassila R**. Antikoagulaatioissa edetään kohti uusia täsmälääkkeitä. (Anticoagulation is progressing towards targeted regimens). Pääkirjoitus, editorial. Suomen Lääkärilehti, 2008;11:1.
64. **Lassila R**. Uudet antikoagulantit. Moodi, 2008
65. **Lassila R**. Antikoagulaatiohoidon kansallinen savotta. (National collaborative effort for anticoagulant therapy). Tabu, 2:4-6;2008
66. Halinen M, **Lassila R**, Miettinen H, Kärkkäinen M, Kaila M. Laskimotukoksen ehkäisy lonkan ja polven elektiivisen tekonivelleikkauksen yhteydessä? Suomen Lääkärilehti, 2008;12-13:1165-9.
67. Raivio P, **Lassila R**, Petäjä J. Thrombin in myocardial ischemia-reperfusion during cardiac surgery. Ann Thoracic Surg, 2009; 88; 318-25.
68. **Lassila R**. Kun sepelvaltimo tukkeutuu poikkeavasti. Sydänääni, 2008.
69. Mustonen P, Halinen M, Melin J, Mustonen P, Niemi T, Puurunen M, **Lassila R**. Sydänpotilaan antitromboottinen lääkitys leikkausten ja pientoimenpiteiden yhteydessä. Duodecim, 2009;125:47-58.
70. **Lassila R**, Klaukka T ja Idänpään-Heikkilä J. Lääkeinfo. Varfariini on edelleen antikoagulaatiohoidon peruslääke. Lääkeinfo. Suomen Lääkärilehti, 7:616-9;2009
71. **Lassila R**. Lääkeinfo. Hematologin kommentti: Antikoagulaatiohoidon parantamiseen hyviä malleja. Suomen Lääkärilehti 20:1891, 2009
72. Joutsu-Korhonen L, Armstrong E, Mäkipernaa A, Asmundela H, Niemistö S, Pinomäki A, **Lassila R**. Laskimotukostaipumus ja potilasohjaus. Suomen Lääkärilehti, 42:3535-40, 2009
73. Heinonen H, **Lassila R**. Laskimotukoksen ehkäisy. (Prevention of venous thrombosis) Matkailijan terveysesopas, 17-18, 2009

74. Perry D, Berntorp E, Tait C, Dolan G, Holme PA, Laffan M, **Lassila R**, Mumford A, Pasi J, Wilde J, Will A, Yee TT. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations. *Haemophilia*. 16:80-9, 2009
75. **Lassila R**, Armstrong E. Current challenges of pharmacovigilance in bleeding disorders: converting burden to benefit. *Haemophilia*, 16:231-7, 2010
76. Armstrong E, Joutsu-Korhonen L, Mäkipernaa A, Asmundela H, Niemistö S, Pinomäki A, **Lassila R**. Verenvuototaipumus ja potilasohjaus. Bleeding diathesis and patient education. *Suomen Lääkärilehti*, 49:4081-9, 2010
78. Venermo M, Ebeling T, Luther M, **Lassila R**, Lepäntalo M. Perifeerinen valtimosairaus, Käypä hoito suositus. *Peripheral Arterial Disease, National Evidence Based – guidelines*. Duodecim 2010
79. **Lassila R**, Pietilä K, Backman J. Antitromboottinen hoito. Antithrombotic treatment. *Kliinisen Farmakologian oppikirja, Textbook of Clinical Pharmacology*, 2010
80. **Lassila R**. Tromboosiprofylaksi, *Ortopedia ja traumatologia*. Duodecim 2009
81. Ahonen J, Stefanovic V, **Lassila R**. Management of post-partum haemorrhage. *Acta Anaesthesiol Scand*, 54:1164-78, 2010.
82. Makris M, Calizzani G, Fischer K, Gilman EA, Hay CRM, **Lassila R**, Lambert T, Ludlam CA, Mannucci PM. EUHASS: The European Haemophilia Safety Surveillance system, *Thromb Res* 127;suppl 2:S22-5, 2011
83. Armstrong E, Joutsu-Korhonen L, **Lassila R**. Interaction between clinic and laboratory, in press, *Thromb Res* 127;suppl 2:S2-, 2011
84. **Lassila R**. the 43rd Nordic Coagulation meeting. *Proceedings Editorial, Introduction*. *Thromb Res* 127;suppl 2:S1, 2011
85. Joutsu-Korhonen L, **Lassila R**, Savolainen E-R. Varfariinihoidon INR-seuranta vieritestauksena – uusi kansallinen suositus, *Lääkeinfo. Suomen Lääkärilehti*, 2010, 11-08
86. **Lassila R**, Manninen H, Kaaja R, Harjola V-P, Halinen M. Laskimotukos ja keuhkoembolia, Käypä hoito suositus. *Update of Evidence Based guidelines in Deep Vein Thrombosis and Pulmonary Embolism*, Duodecim 2010
87. **Lassila R**, Joutsu-Korhonen L, Armstrong E, Holme PA, Hillarp A, Holmström M, Fariba B, Jonhsson H, Antovic J, Daalsgard-Nielsen J, Sandset P.M. Practical diagnosis and management of heparin-induced thrombocytopenia. *Semin Thromb Haemost*, 37:328-36, 2011
88. **Lassila R**, Holme PA, Landorph A, Petrini P, Onunardson PT, Hillarp A. Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease. *Semin Thromb Haemost*, 37:495-502, 2011.
89. **Lassila R**, Kallio J. Antitromboottinen lääkehoito. *Farmakologian oppikirja. Textbook of Pharmacology*. 2011
90. Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A, Holme PA et al. for the European Haemophilia Therapy Standardisation Board. Non-genetic risk factors and the development of inhibitors in Haemophilia A: a comprehensive review and consensus report. *Haemophilia* 16:747-66, 2010
91. Hermans C, deMoerloose P, Fischer K, Holstein K, Klamroth R, Lambert T, et al for the European Hemophilia Therapy Standardisation Board. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. *Haemophilia* 17;383-92, 2011

92. Update on current care guidelines: cerebral infarction, stroke. Article in Finnish. *Duodecim* 127;500-1, 2011
93. **Lassila R**, ym. Uusien antikoagulanttien hallittu käyttöönotto, *Suomen Lääkärilehti*, 35:2753-62, 2011
94. Virtanen L, ym. Tromboosiprofylaksi suomalaisessa sairaanhoidossa. *Suomen Lääkärilehti* 65:1319–26. 2010
95. Salmela B, Joutsu-Korhonen L, Armstrong E, **Lassila R**. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance and coagulation analysis. *Semin Thromb Haemostas* 38:23-30, 2012
96. Szanto T, Joutsu-Korhonen L, Deckmyn H, **Lassila R**. New insights into von Willebrand disease and platelet function. *Semin Thromb Haemostas* 38:55-63, 2012
97. **Lassila R**. Hemostaasi ja tromboosi. s. 424-432, *Patologia*. Toim. Mäkinen M., Carpen O, Kosma V-M, Lehto V-P, Paavonen T, Stenbäck F. *Duodecim*, Helsinki, Finland. Hemostasis and thrombosis. Textbook of Pathology
98. **Lassila R**. Role and management of coagulation disorders in peripheral arterial disease. *Scandinavian Journal of Surgery*, Special issue: Critical limb ischaemia - from art to evidence Guest editors: M. Venermo, M. Björck, 101:1-6, 2012
99. Norja P, **Lassila R**, Makris M. Parvovirus by blood products – a cause of concern? *Brit J Hematol*, 159:385-93, 2012
100. Österholm K, Puustjärvi-Sunabacka K, Alberty A, **Lassila R**, Armstrong E. Suomen Lääkärilehti, Vaikeaa verenvuototautia sairastavat potilaat hyötyvät moniammatillisesta hoidosta ja kuntoutuksesta. *Suomen Lääkärilehti*, 42;3015- 20, 2012.
101. Berntorp E, Peake I, Budde U, Laffan M, Montgomery R, Windyga J, Goodeve A, Petrini P, von Depka M, Miesbach W, Lillicrap D, Federici A, **Lassila R**, White C. von Willebrand disease: a report from a meeting in the Åland island. *Haemophilia* 18; suppl 6:1-13, 2012
102. Åberg F, **Lassila R**, Koivusalo A-M, Numminen K, Nuutinen H, Mäkisalo H. Maksan vajaatoiminta ja hemostaasi – verenvuotovaaran arviointi. Liver disease and hemostasis – evaluation of bleeding risk. *Duodecim*; 128:1971-80;2012
103. Janes R, **Lassila R**. 51.34 Syvä laskimotukos ja keuhkoembolia. Syöpätaudit, 2013,ss. 949-951 *Duodecim*. Editors Joensuu H, Roberts PJ, Kellokumpu-Laitinen P-L, Jyrkkö S, Kouri M, Lyly T.
104. **Lassila R**. The role of platelets in hemophilia. *International Monitor in Hemophilia*, 2013
105. **Lassila R**, Lindberg O. Comemorative article. Erik von Willebrand. *Haemophilia* 19: 543-547;2013
106. **Lassila R**, Joutsu-Korhonen L. 8.6. Pysyvä tai pitkäaikainen antikoagulaatiohoito. Long-term or permanent anticoagulant treatment. *Lasten Kardiologian oppikirja*, *Duodecim*, Textbook of pediatric Cardiology, 2013.
107. Helin T, Metso T, Holvitie J, Valtonen K, **Lassila R**, Mäki T, Joutsu-Korhonen L. TTR kuvastaa varfariinihoidon laatua. *Suomen Lääkärilehti*, 2013;38:2384-5.
108. **Lassila R**, Laasila K, Asmundela H, Armstrong E. Suorat oraaliset antikoagulantit – avoimia kysymyksiä. *Lääkeinfo*. Direct oral anticoagulants – open issues. *Suomen Lääkärilehti* 2014, *Finnish Medical Journal*
109. Makris M, Calizzani G, Fischer K, Gatt A, Gilman E, Hollingsworth R, Lambert T, **Lassila R**, Mannucci PM, Peyvandi F, and Windyga J. The European Haemophilia Network (EUHANET). *J Transfusion* 2014;12,suppl 3;515-8.
110. Astermark J, Dolan G, Hilberg T, Jiménez-Yuste V, Laffan M, **Lassila R**, Lobet S, Martinoli C, Perno CF. Managing haemophilia for life: 4th Haemophilia Global Summit. *Haemophilia* 2014;20 Suppl 5:1-20. doi: 10.1111/hae.12468

111. **Lassila R**, Janes R. Hyytymishäiriöt palliatiivisessa hoidossa. Oppikirja: Palliatiivinen hoito. Eds, Saarto Duodecim, 2014.
112. **Lassila R**. Hemostaasi, perinnölliset verenvuototaudit, trombofiliat In Chapter 15, Therapia Fennica, Erkki Elonen, editor, Kandidaattiseura, pp.4-78, 2014
113. **Lassila R** and Makris M. Safety surveillance in haemophilia and allied disorders, J Int Med, in press 2015
114. **Lassila R**, Armstrong E. Acquired inhibitors of coagulation. Practical Haemostasis and Thrombosis, 3<sup>rd</sup> edition, eds. Nigel Key, Mike Makris and David Lillicrap. in press 2015
115. Heidbuchel H, Berti D, Campos M, Desteghe L, Freixo A, Nunes A, Roldán V, Toschi V, **Lassila R**, Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. Thrombosis Journal;13:22:1-14, 2015
116. **Lassila R**. Platelet function testing (invited). Semin Thromb Hemost, 2015, in press
117. **Lassila R**. Heparin-induced thrombocytopenia. Handbook of nutrition and diet in leukemia and blood disease therapy, 2015, in press
118. Carcao M, Fukutake K, Inbal A, Kerlin B, **Lassila R**, Oldenburg J, Garly M-L, Nugentt D. Developing the first recombinant Factor XIII for congenital Factor XIII deficiency: clinical challenges and successes. Thromb Haemostas, submitted, 2015.
119. **Lassila R**. Statins and venous thromboembolism. Ann Med, submitted Jan 2016
120. **Lassila R**. Factor XIII concentrates (invited). Semin Thromb Hemostas, in press 2016